ZIEXTENZO 6mg injection solution in pre-filled syringe medication leaflet

Ziextenzo 6 mg solution for injection in pre-filled syringe

Each pre-filled syringe contains 6 mg of pegfilgrastim* in 0.6 mL solution for injection. Theconcentration is 10 mg/mL based on protein only**.

*Produced in Escherichia coli cells by recombinant DNA technology followed by conjugation withpolyethylene glycol (PEG).

** The concentration is 20 mg/mL if the PEG moiety is included.

The potency of this product should not be compared to the potency of another pegylated ornon-pegylated protein of the same therapeutic class. For more information, see section 5.1

Each pre-filled syringe contains 30 mg sorbitol (E420).

For the full list of excipients, see section 6.1.

Solution for injection (injection)

Clear, colourless to slightly yellowish solution for injection.

Reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patientstreated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemiaand myelodysplastic syndromes).

Ziextenzo therapy should be initiated and supervised by physicians experienced in oncology and/orhaematology.

One 6 mg dose (a single pre-filled syringe) of Ziextenzo is recommended for each chemotherapy cycle,given at least 24 hours after cytotoxic chemotherapy.

The safety and efficacy of pegfilgrastim in children has not yet been established. Currently availabledata are described in sections 4.8, 5.1 and 5.2 but no recommendation on a posology can be made.

No dose change is recommended in patients with renal impairment, including those with end stage renaldisease.

Ziextenzo is for subcutaneous use.

The injections should be given into the thigh, abdomen or upper arm. For instructions on handling of themedicinal product before administration, see section 6.6.

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

In order to improve the traceability of biological medicinal products, the name and the batch number ofthe administered product should be clearly recorded.

General warnings and precautions

Limited clinical data suggest a comparable effect on time to recovery of severe neutropenia forpegfilgrastim to filgrastim in patients with de novo acute myeloid leukaemia (AML) (see section 5.1).

However, the long-term effects of pegfilgrastim have not been established in AML; therefore, it shouldbe used with caution in this patient population.

Granulocyte-colony stimulating factor (G-CSF) can promote growth of myeloid cells in vitro andsimilar effects may be seen on some non-myeloid cells in vitro.

The safety and efficacy of pegfilgrastim have not been investigated in patients with myelodysplasticsyndrome, chronic myelogenous leukaemia, and in patients with secondary AML; therefore, it shouldnot be used in such patients. Particular care should be taken to distinguish the diagnosis of blasttransformation of chronic myeloid leukaemia from AML.

The safety and efficacy of pegfilgrastim administration in de novo AML patients aged < 55 years withcytogenetics t(15;17) have not been established.

The safety and efficacy of pegfilgrastim have not been investigated in patients receiving high dosechemotherapy. This medicinal product should not be used to increase the dose of cytotoxicchemotherapy beyond established dose regimens.

Pulmonary adverse events

Pulmonary adverse reactions, in particular interstitial pneumonia, have been reported after G-CSFadministration. Patients with a recent history of pulmonary infiltrates or pneumonia may be at higherrisk (see section 4.8).

The onset of pulmonary signs such as cough, fever, and dyspnoea in association with radiological signsof pulmonary infiltrates, and deterioration in pulmonary function along with increased neutrophil countmay be preliminary signs of Acute Respiratory Distress Syndrome (ARDS). In such circumstancespegfilgrastim should be discontinued at the discretion of the physician and the appropriate treatmentgiven (see section 4.8).

Glomerulonephritis

Glomerulonephritis has been reported in patients receiving filgrastim and pegfilgrastim. Generally,events of glomerulonephritis resolved after dose reduction or withdrawal of filgrastim and pegfilgrastim.

Urinalysis monitoring is recommended.

Capillary leak syndrome has been reported after granulocyte-colony stimulating factor administrationand is characterised by hypotension, hypoalbuminaemia, oedema and haemoconcentration. Patients whodevelop symptoms of capillary leak syndrome should be closely monitored and receive standardsymptomatic treatment, which may include a need for intensive care (see section 4.8).

Splenomegaly and splenic rupture

Generally asymptomatic cases of splenomegaly and cases of splenic rupture, including some fatal cases,have been reported following administration of pegfilgrastim (see section 4.8). Therefore, spleen sizeshould be carefully monitored (e.g. clinical examination, ultrasound). A diagnosis of splenic ruptureshould be considered in patients reporting left upper abdominal pain or shoulder tip pain.

Thrombocytopenia and anaemia

Treatment with pegfilgrastim alone does not preclude thrombocytopenia and anaemia because full dosemyelosuppressive chemotherapy is maintained on the prescribed schedule. Regular monitoring ofplatelet count and haematocrit is recommended. Special care should be taken when administering singleor combination chemotherapeutic agents which are known to cause severe thrombocytopenia.

Myelodysplastic syndrome and acute myeloid leukaemia in breast and lung cancer patients

In the post-marketing observational study setting, pegfilgrastim in conjunction with chemotherapyand/or radiotherapy has been associated with development of myelodysplastic syndrome (MDS) andacute myeloid leukaemia (AML) in breast and lung cancer patients (see section 4.8). Monitor breastand lung cancer patients for signs and symptoms of MDS/AML.

Sickle cell anaemia

Sickle cell crises have been associated with the use of pegfilgrastim in patients with sickle cell trait orsickle cell disease (see section 4.8). Therefore, physicians should use caution when prescribingpegfilgrastim in patients with sickle cell trait or sickle cell disease, should monitor appropriate clinicalparameters and laboratory status and be attentive to the possible association of this medicine withsplenic enlargement and vaso-occlusive crisis.

Leukocytosis

White blood cell (WBC) counts of 100 × 109/L or greater have been observed in less than 1% of patientsreceiving pegfilgrastim. No adverse events directly attributable to this degree of leukocytosis have beenreported. Such elevation in white blood cells is transient, typically seen 24 to 48 hours afteradministration and is consistent with the pharmacodynamic effects of this medicine. Consistent with theclinical effects and the potential for leukocytosis, a WBC count should be performed at regular intervalsduring therapy. If leukocyte counts exceed 50 × 109/L after the expected nadir, this medicine should bediscontinued immediately.

Hypersensitivity, including anaphylactic reactions, occurring on initial or subsequent treatment has beenreported in patients treated with pegfilgrastim. Permanently discontinue pegfilgrastim in patients withclinically significant hypersensitivity. Do not administer pegfilgrastim to patients with a history ofhypersensitivity to pegfilgrastim or filgrastim. If a serious allergic reaction occurs, appropriate therapyshould be administered, with close patient follow-up over several days.

Stevens-Johnson syndrome

Stevens-Johnson syndrome (SJS), which can be life-threatening or fatal, has been reported rarely inassociation with pegfilgrastim treatment. If the patient has developed SJS with the use of pegfilgrastim,treatment with pegfilgrastim must not be restarted in this patient at any time.

As with all therapeutic proteins, there is a potential for immunogenicity. Rates of generation ofantibodies against pegfilgrastim are generally low. Binding antibodies do occur as expected with allbiologics; however, they have not been associated with neutralising activity at present.

Aortitis

Aortitis has been reported after G-CSF administration in healthy subjects and in cancer patients. Thesymptoms experienced included fever, abdominal pain, malaise, back pain and inflammatory markers(e.g. C-reactive protein and white blood cell count) were raised. In most cases aortitis was diagnosed by

CT scan and generally resolved after withdrawal of G-CSF. See also section 4.8.

The safety and efficacy of pegfilgrastim for the mobilisation of blood progenitor cells in patients orhealthy donors have not been adequately evaluated.

Increased haematopoietic activity of the bone marrow in response to growth factor therapy has beenassociated with transient positive bone-imaging findings. This should be considered when interpretingbone-imaging results.

This medicinal product contains 30 mg sorbitol in each pre-filled syringe which is equivalent to50 mg/mL. The additive effect of concomitantly administered products containing sorbitol (or fructose)and dietary intake of sorbitol (or fructose) should be taken into account.

This medicinal product contains less than 1 mmol sodium (23 mg) per 6 mg dose, that is to sayessentially ‘sodium-free’.

Due to the potential sensitivity of rapidly dividing myeloid cells to cytotoxic chemotherapy‚pegfilgrastim should be administered at least 24 hours after administration of cytotoxic chemotherapy. Inclinical trials, pegfilgrastim has been safely administered 14 days before chemotherapy. Concomitantuse of pegfilgrastim with any chemotherapy agent has not been evaluated in patients. In animal modelsconcomitant administration of pegfilgrastim and 5-fluorouracil (5-FU) or other antimetabolites has beenshown to potentiate myelosuppression.

Possible interactions with other haematopoietic growth factors and cytokines have not been specificallyinvestigated in clinical trials.

The potential for interaction with lithium, which also promotes the release of neutrophils, has not beenspecifically investigated. There is no evidence that such an interaction would be harmful.

The safety and efficacy of pegfilgrastim have not been evaluated in patients receiving chemotherapyassociated with delayed myelosuppression e.g. nitrosoureas.

Specific interaction or metabolism studies have not been performed, however, clinical trials have notindicated an interaction of pegfilgrastim with any other medicinal products.

There are no or limited amount of data from the use of pegfilgrastim in pregnant women. Studies inanimals have shown reproductive toxicity (see section 5.3). Pegfilgrastim is not recommended duringpregnancy and in women of childbearing potential not using contraception.

There is insufficient information on the excretion of pegfilgrastim/metabolites in human milk, a risk tothe newborns/infants cannot be excluded. A decision must be made whether to discontinuebreast-feeding or to discontinue/abstain from pegfilgrastim therapy taking into account the benefit ofbreast-feeding for the child and the benefit of therapy for the woman.

Pegfilgrastim did not affect reproductive performance or fertility in male or female rats at cumulativeweekly doses approximately 6 to 9 times higher than the recommended human dose (based on bodysurface area) (see section 5.3).

Pegfilgrastim has no or negligible influence on the ability to drive and use machines.

The most frequently reported adverse reactions were bone pain (very common [≥ 1/10]) andmusculoskeletal pain (common [≥ 1/100 to < 1/10]). Bone pain was generally of mild to moderateseverity, transient and could be controlled in most patients with standard analgesics.

Hypersensitivity-type reactions, including skin rash, urticaria, angioedema, dyspnoea, erythaema,flushing, and hypotension occurred on initial or subsequent treatment with pegfilgrastim (uncommon[≥ 1/1 000 to < 1/100]). Serious allergic reactions, including anaphylaxis can occur in patients receivingpegfilgrastim (uncommon) (see section 4.4).

Capillary Leak Syndrome, which can be life-threatening if treatment is delayed, has been reported asuncommon (≥ 1/1 000 to < 1/100) in cancer patients undergoing chemotherapy following administrationof granulocyte colony-stimulating factors; see section 4.4 and section “Description of selected adversereactions” below.

Splenomegaly, generally asymptomatic, is uncommon.

Splenic rupture including some fatal cases is uncommonly reported following administration ofpegfilgrastim (see section 4.4).

Uncommon pulmonary adverse reactions including interstitial pneumonia, pulmonary oedema,pulmonary infiltrates and pulmonary fibrosis have been reported. Uncommonly, cases have resulted inrespiratory failure or ARDS, which may be fatal (see section 4.4).

Isolated cases of sickle cell crises have been reported in patients with sickle cell trait or sickle celldisease (uncommon in sickle cell patients) (see section 4.4).

The data in the table below describe adverse reactions reported from clinical trials and spontaneousreporting. Within each frequency grouping,adverse reactions are presented in order of decreasing seriousness.

Table 1. Adverse reactions

MedDRA Adverse reactionssystem organ Very Common Uncommon Rareclass common (≥ 1/100 to < 1/10) (≥ 1/1 000 to < 1/100) (≥ 1/10 000(≥ 1/10) to< 1/1 000)

Neoplasms Myelodysplasticbenign, syndrome1malignant and Acute myeloidunspecified 1(incl cysts and leukaemiapolyps)

Blood and Thrombocytopenia1 Sickle cell anaemialymphatic Leukocytosis1 with crisis2system Splenomegaly2;Splenicdisorders rupture2

Immune system Hypersensitivitydisorders reactions; Anaphylaxis

Metabolism Elevations in uric acidand nutritiondisorders

Nervous system Headache1disorders

Vascular Capillary leak Aortitisdisorders syndrome1

Respiratory, Acute respiratory Pulmonarythoracic and distress syndrome2 haemorrhagemediastinal Pulmonary adversedisorders reactions (interstitialpneumonia, pulmonaryoedema, pulmonaryinfiltrates andpulmonary fibrosis)

Haemoptysis

Gastrointestinal Nausea1disorders

Skin and Sweet’s syndrome Stevens-subcutaneous (acute febrile Johnsontissue disorders neutrophilic syndromedermatosis)1,2

Cutaneous vasculitis1,2

MedDRA Adverse reactionssystem organ Very Common Uncommon Rareclass common (≥ 1/100 to < 1/10) (≥ 1/1 000 to < 1/100) (≥ 1/10 000(≥ 1/10) to< 1/1 000)

Musculoskeletal Bone pain Musculoskeletaland connective pain (myalgia,tissue disorders arthralgia, pain inextremity, backpain, musculo-skeletal pain, neckpain)

Renal and Glomerulonephritis2urinarydisorders

General Injection site pain1 Injection sitedisorders and Non-cardiac chest reactions2administrative painsite conditions

Investigations Elevations in lactatedehydrogenase andalkalinephosphatase1Transientelevations in LFT's for

ALT or AST11 See section “Description of selected adverse reactions” below.2 This adverse reaction was identified through post-marketing surveillance but not observed inrandomised, controlled clinical trials in adults. The frequency category was estimated from a statisticalcalculation based upon 1 576 patients receiving pegfilgrastim in nine randomised clinical trials.

Uncommon cases of Sweet’s syndrome have been reported, although in some cases underlyinghaematological malignancies may play a role.

Uncommon events of cutaneous vasculitis have been reported in patients treated with pegfilgrastim. Themechanism of vasculitis in patients receiving pegfilgrastim is unknown.

Injection site reactions, including injection site erythaema (uncommon) as well as injection site pain(common) have occurred on initial or subsequent treatment with pegfilgrastim.

Common cases of leukocytosis (White Blood Count [WBC] > 100 × 109/L) have been reported (seesection 4.4).

Reversible, mild to moderate elevations in uric acid and alkaline phosphatase, with no associated clinicaleffects, were uncommon; reversible, mild to moderate elevations in lactate dehydrogenase, with noassociated clinical effects, were uncommon in patients receiving pegfilgrastim following cytotoxicchemotherapy.

Nausea and headaches were very commonly observed in patients receiving chemotherapy.

Uncommon elevations in liver function tests (LFTs) for alanine aminotransferase (ALT) or aspartateaminotransferase (AST), have been observed in patients after receiving pegfilgrastim followingcytotoxic chemotherapy. These elevations are transient and return to baseline.

An increased risk of MDS/AML following treatment with Ziextenzo in conjunction withchemotherapy and/or radiotherapy has been observed in an epidemiological study in breast andlung cancer patients (see section 4.4).

Common cases of thrombocytopenia have been reported.

Cases of capillary leak syndrome have been reported in the post-marketing setting with granulocytecolony-stimulating factor use. These have generally occurred in patients with advanced malignantdiseases, sepsis, taking multiple chemotherapy medicinal products or undergoing apheresis (seesection 4.4).

The experience in children is limited. A higher frequency of serious adverse reactions in youngerchildren aged 0-5 years (92%) has been observed compared to older children aged 6-11 and 12-21 yearsrespectively (80% and 67%) and adults. The most common adverse reaction reported was bone pain (seesections 5.1 and 5.2).

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allowscontinued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals areasked to report any suspected adverse reactions via the national reporting system listed in Appendix V.

Single doses of 300 mcg/kg have been administered subcutaneously to a limited number of healthyvolunteers and patients with non-small cell lung cancer without serious adverse reactions. The adverseevents were similar to those in subjects receiving lower doses of pegfilgrastim.

Pharmacotherapeutic group: immunostimulants, colony stimulating factor; ATC Code: L03AA13

Ziextenzo is a biosimilar medicinal product. Detailed information is available on the website of the

European Medicines Agency http://www.ema.europa.eu.

Human granulocyte colony stimulating factor (G-CSF) is a glycoprotein, which regulates the productionand release of neutrophils from the bone marrow. Pegfilgrastim is a covalent conjugate of recombinanthuman G-CSF (r-metHuG-CSF) with a single 20 kd polyethylene glycol (PEG) molecule. Pegfilgrastimis a sustained duration form of filgrastim due to decreased renal clearance.

Pegfilgrastim and filgrastim have been shown to have identical modes of action, causing a markedincrease in peripheral blood neutrophil counts within 24 hours, with minor increases in monocytesand/or lymphocytes. Similarly to filgrastim, neutrophils produced in response to pegfilgrastim shownormal or enhanced function as demonstrated by tests of chemotactic and phagocytic function. As withother haematopoietic growth factors, G-CSF has shown in vitro stimulating properties on humanendothelial cells. G-CSF can promote growth of myeloid cells, including malignant cells, in vitro andsimilar effects may be seen on some non-myeloid cells in vitro.

In two randomised, double-blind, pivotal studies in patients with high-risk stage II-IV breast cancerundergoing myelosuppressive chemotherapy consisting of doxorubicin and docetaxel, use ofpegfilgrastim, as a single once per cycle dose, reduced the duration of neutropenia and the incidence offebrile neutropenia similarly to that observed with daily administrations of filgrastim (a median of11 daily administrations). In the absence of growth factor support, this regimen has been reported toresult in a mean duration of grade 4 neutropenia of 5 to7 days, and a 30-40% incidence of febrileneutropenia. In one study (n = 157), which used a 6 mg fixed dose of pegfilgrastim the mean duration ofgrade 4 neutropenia for the pegfilgrastim group was 1.8 days compared with 1.6 days in the filgrastimgroup (difference 0.23 days, 95% CI -0.15, 0.63). Over the entire study, the rate of febrile neutropeniawas 13% of pegfilgrastim-treated patients compared with 20% of filgrastim-treated patients (difference7%, 95% CI of -19%, 5%). In a second study (n = 310), which used a weight-adjusted dose(100 mcg/kg), the mean duration of grade 4 neutropenia for the pegfilgrastim group was 1.7 days,compared with 1.8 days in the filgrastim group (difference 0.03 days, 95% CI-0.36, 0.30). The overallrate of febrile neutropenia was 9% of patients treated with pegfilgrastim and 18% of patients treatedwith filgrastim (difference 9%, 95% CI of -16.8%, -1.1%).

In a placebo-controlled, double blind study in patients with breast cancer the effect of pegfilgrastim onthe incidence of febrile neutropenia was evaluated following administration of a chemotherapy regimenassociated with a febrile neutropenia rate of 10-20% (docetaxel 100 mg/m2 every 3 weeks for 4 cycles).

Nine hundred and twenty eight patients were randomised to receive either a single dose of pegfilgrastimor placebo approximately 24 hours (day 2) after chemotherapy in each cycle. The incidence of febrileneutropenia was lower for patients randomised to receive pegfilgrastim compared with placebo (1%versus 17%, p < 0.001). The incidence of hospitalisations and IV anti-infective use associated with aclinical diagnosis of febrile neutropenia was lower in the pegfilgrastim group compared with placebo(1% versus 14%, p < 0.001; and 2% versus 10%, p < 0.001).

A small (n = 83), phase II, randomised, double-blind study in patients receiving chemotherapy for denovo acute myeloid leukaemia compared pegfilgrastim (single dose of 6 mg) with filgrastim,administered during induction chemotherapy. Median time to recovery from severe neutropenia wasestimated as 22 days in both treatment groups. Long term outcome was not studied (see section 4.4).

In a phase II (n = 37) multicentre, randomised, open-label study of paediatric sarcoma patients receiving100 mcg/kg pegfilgrastim following cycle 1 of vincristine, doxorubicin and cyclophosphamide(VAdriaC/IE) chemotherapy, a longer duration of severe neutropenia (neutrophils < 0.5 × 109/L) wasobserved in younger children aged 0-5 years (8.9 days) compared to older children aged 6-11 years and12-21 years (6 days and 3.7 days, respectively) and adults. Additionally a higher incidence of febrileneutropenia was observed in younger children aged 0-5 years (75%) compared to older children aged6-11 years and 12-21 years (70% and 33%, respectively) and adults (see sections 4.8 and 5.2).

After a single subcutaneous dose of pegfilgrastim, the peak serum concentration of pegfilgrastim occursat 16 to 120 hours after dosing and serum concentrations of pegfilgrastim are maintained during theperiod of neutropenia after myelosuppressive chemotherapy. The elimination of pegfilgrastim isnon-linear with respect to dose; serum clearance of pegfilgrastim decreases with increasing dose.

Pegfilgrastim appears to be mainly eliminated by neutrophil mediated clearance, which becomessaturated at higher doses. Consistent with a self-regulating clearance mechanism, the serumconcentration of pegfilgrastim declines rapidly at the onset of neutrophil recovery (see Figure 1).

Figure 1. Profile of median pegfilgrastim serum concentration and absolute neutrophil count(ANC) in chemotherapy treated patients after a single 6 mg injection

Due to the neutrophil-mediated clearance mechanism, the pharmacokinetics of pegfilgrastim is notexpected to be affected by renal or hepatic impairment. In an open-label, single dose study (n = 31)various stages of renal impairment, including end-stage renal disease, had no impact on thepharmacokinetics of pegfilgrastim.

Limited data indicate that the pharmacokinetics of pegfilgrastim in elderly subjects (> 65 years) issimilar to that in adults.

The pharmacokinetics of pegfilgrastim were studied in 37 paediatric patients with sarcoma, whoreceived 100 mcg/kg pegfilgrastim after the completion of VAdriaC/IE chemotherapy. The youngest agegroup (0-5 years) had a higher mean exposure to pegfilgrastim (AUC) (± Standard Deviation)(47.9 ± 22.5 mcg·hr/ml) than older children aged 6-11 years and 12-21 years (22.0 ± 13.1 mcg hr/ml and29.3 ± 23.2 mcg·hr/ml, respectively) (see section 5.1). With the exception of the youngest age group(0-5 years), the mean AUC in paediatric subjects appeared similar to that for adult patients withhigh-risk stage II-IV breast cancer and receiving 100 mcg/kg pegfilgrastim after the completion ofdoxorubicin/docetaxel (see sections 4.8 and 5.1).

Preclinical data from conventional studies of repeated dose toxicity revealed the expectedpharmacological effects including increases in leukocyte count, myeloid hyperplasia in bone marrow,extramedullary haematopoiesis and splenic enlargement.

There were no adverse effects observed in offspring from pregnant rats given pegfilgrastimsubcutaneously, but in rabbits pegfilgrastim has been shown to cause embryo/foetal toxicity (embryoloss) at cumulative doses approximately 4 times the recommended human dose, which were not seenwhen pregnant rabbits were exposed to the recommended human dose. In rat studies, it was shown thatpegfilgrastim may cross the placenta. Studies in rats indicated that reproductive performance, fertility,oestrous cycling, days between pairing and coitus, and intrauterine survival were unaffected bypegfilgrastim given subcutaneously. The relevance of these findings for humans is not known.

Glacial acetic acid

Sorbitol (E420)

Polysorbate 20

Sodium hydroxide (for pH adjustment)

Water for injections

This medicinal product must not be mixed with other medicinal products, particularly with sodiumchloride solutions.

3 years.

Store in a refrigerator (2 °C-8 °C).

Ziextenzo may be exposed to room temperature (not above 35 °C) for a maximum single period of up to120 hours. Ziextenzo left at room temperature for more than 120 hours should be discarded.

Do not freeze. Accidental exposure to freezing temperatures for a single period of less than 24 hoursdoes not adversely affect the stability of Ziextenzo.

Keep the container in the outer carton in order to protect from light.

Pre-filled syringe (Type I glass), with a rubber plunger stopper (bromobutyl rubber, latex-free), aplunger rod, a stainless steel 29 gauge needle and a rubber needle cap (thermoplastic elastomer, latex-free) with an automatic needle guard.

Each pre-filled syringe contains 0.6 ml of solution for injection.

Pack size of one pre-filled syringe in a blistered packaging.

Before use, Ziextenzo solution should be inspected visually for particulate matter. Only a solution that isclear and colourless to slightly yellowish should be injected.

Excessive shaking may aggregate pegfilgrastim, rendering it biologically inactive.

Allow the pre-filled syringe to reach room temperature for 15-30 minutes before using the syringe.

Any unused product or waste material should be disposed of in accordance with local requirements.

Sandoz GmbH

Biochemiestr. 106250 Kundl

Austria

EU/1/18/1327/001

Date of first authorisation: 22 November 2018

Date of latest renewal: 23 June 2023

Detailed information on this medicinal product is available on the website of the European Medicines

Agency http://www.ema.europa.eu.